Immunotherapy with a JAK1/JAK2 inhibitor (baricitinib) and an mTORC1 inhibitor (sirolimus), alone and in combination, for the control of HIV-1 replication after antiretroviral treatment interruption: a phase II multicenter, multi-arm, multi-stage, randomized, double-blind, placebo-controlled, adaptative trial
Most people living with HIV take daily antiretroviral therapy (ART) to keep the virus suppressed. If ART is stopped, the virus almost always returns. This Phase II clinical trial investigates whether two medicines, called baricitinib and sirolimus, can help the body control HIV without daily ART. In this study, participants pause their regular HIV medication under strict medical supervision and take the study medicines or a dummy pill (placebo). Doctors will closely check blood tests to see if the virus stays asleep. The main aim is to find out how long people can safely stay off standard ART before the virus starts to rise again or immune cells drop. If the virus returns at any point, standard HIV treatment is restarted straight away to keep participants safe. The trial tracks participants for about 50 weeks.
A colpo d'occhio
Di cosa tratta questo studio?
Current HIV treatments, known as antiretroviral therapy (ART), are very effective. They reduce the virus to undetectable levels, meaning people can live long, healthy lives and cannot pass the virus on. However, ART does not cure HIV because tiny amounts of the virus remain sleeping inside immune cells. Because of this, people must take ART every day for life.
This study explores an approach called immunotherapy. Researchers are testing two medicines, baricitinib and sirolimus. Baricitinib is normally used for conditions like rheumatoid arthritis, while sirolimus is used to calm the immune system after kidney transplants. Scientists believe these medicines might calm inflammation and stop resting HIV cells from multiplying, allowing the body to keep the virus asleep naturally.
To see if these medicines work, volunteers will temporarily stop their standard ART while taking the study drugs or an inactive placebo. Pausing treatment in a controlled study is known as an 'analytical treatment interruption'. While pausing treatment carries some risks, it is currently the only reliable way for scientists to see if a new therapy can truly keep HIV under control on its own.
Punti chiave
- Tests whether baricitinib and sirolimus can control HIV without daily standard medication.
- Participants will carefully pause their usual HIV treatment under close medical supervision.
- Open to adults aged 18 and older living with HIV-1 who have an undetectable viral load.
- Involves regular clinic visits and blood tests over approximately 50 weeks.
- Standard HIV treatment is restarted immediately if the virus rises or CD4 cells fall.
Chi può essere idoneo?
This trial is open to adults aged 18 and over who have been diagnosed with HIV-1. To take part, you will usually need to be on stable antiretroviral therapy (ART) with an undetectable viral load for a certain period, and have a healthy immune system with good CD4 cell counts.
You may not be able to join if you have other serious medical conditions, such as severe kidney or liver disease, active hepatitis, or recent serious infections. Women who are pregnant or planning to become pregnant are also generally excluded, as the safety of these medicines during pregnancy is not fully known.
The research team will review your complete medical history and perform detailed blood tests to confirm whether it is safe for you to take part.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- I am aged 18 or older.
- I have been diagnosed with HIV-1.
- I am currently taking daily HIV medication (ART).
- My viral load has been undetectable on stable treatment.
- I am willing to attend regular hospital appointments and blood tests.
Cosa comporta la partecipazione?
If you decide to take part, your participation will last around 50 weeks. The trial begins with a screening visit to check your general health and immune system. You will then be randomly assigned (like drawing straws) to take either baricitinib, sirolimus, both together, or matching dummy pills (placebos).
During the study, you will stop taking your regular HIV treatment under careful guidance. You will have frequent clinic visits, especially during the first few months, for safety checks and blood tests. These tests measure your viral load and CD4 immune cell counts. If your virus bounces back, or if your CD4 count drops below a safe level, you will immediately restart your standard ART. The study team will continue to monitor your health until your viral load is undetectable again.
Rischi e benefici potenziali
Luoghi (1)
- —Non verificatoFrancia
Domande comuni
Why do I have to pause my regular HIV treatment?
Pausing your treatment is the only way researchers can see if the new medicines can hold back HIV on their own. This is done with frequent blood tests to ensure you remain safe.
Can I pass HIV to a partner while on this trial?
Yes, if your viral load rises while off standard treatment, the 'Undetectable = Untransmittable' (U=U) rule may no longer apply. You will need to use effective barrier methods, like condoms, or your partner may need to take PrEP during this time.
What happens if my viral load goes back up?
If your viral load rises to a specific level, the doctors will ask you to restart your standard HIV medication immediately. You will be monitored until the virus is undetectable again.
Che cos'è un placebo?
A placebo is a harmless dummy pill that looks identical to the real medicine. It helps researchers prove whether any improvements or side effects are truly caused by the study drug.
Can I leave the study early if I change my mind?
Yes. You have the right to leave the trial at any time without giving a reason. Your standard NHS HIV care will not be affected in any way.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.